Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe
Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.
Brand Name : Mesulid
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 24, 2024
Lead Product(s) : Nimesulide
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Angelini Pharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?